

COLLOQUE ABC FRANCO - BELGE / FRENCH - BELGIAN ABC MEETING



# Antibiotic efflux in eucaryotic cells: implications of ABC transporters and pharmacokinetic and pharmacodynamic consequences

## Françoise Van Bambeke

Pharmacologie cellulaire et moléculaire Université catholique de Louvain Brussels, Belgium

www.facm.ucl.ac.be

## **Antibiotics as substrates of MDR transporters**



### **P-glycoprotein**

- $\rightarrow$  macrolides, rifampicin
- $\rightarrow$  anticancer agents
- $\rightarrow$  antidepressants, antiepileptics
- $\rightarrow$  digoxin
- $\rightarrow \dots$

#### MRP

- $\rightarrow$  fluoroquinolones,  $\beta$ -lactams
- $\rightarrow$  antiviral agents
- $\rightarrow$  anticancer agents
- $\rightarrow$  drug conjugates
- $\rightarrow \dots$

## **Antibiotics as substrates of MDR transporters**

## → Pharmacokinetic implications → Pharmacodynamic implications



#### intracellular infections



Van Bambeke et al, JAC. (2003) 51:1067-77

# Different behavior of closely structurally-related quinolones

ciprofloxacin

moxifloxacin





extracell. conc. 17 mg/L; probenecid 5 mM

# Kinetics of accumulation and efflux for ciprofloxacin

### both accumulation and efflux markedly affected by MRP inhibitors



## Kinetics of accumulation and efflux for moxifloxacin

### neither accumulation nor efflux affected by MRP inhibitors



## **Quinolones as inhibitors of ciprofloxacin efflux**

### ciprofloxacin efflux inhibited by ciprofloxacin



## **Quinolones as inhibitors of ciprofloxacin efflux**

- ciprofloxacin efflux inhibited by ciprofloxacin
- moxifloxacin not affected



# **Quinolones as inhibitors of ciprofloxacin efflux**

## ciprofloxacin efflux inhibited by ciprofloxacin moxifloxacin



## Putative mechanism of transport of quinolones by MRP

## ciprofloxacin

## moxifloxacin





" classical " model

" futile cycle "

# Can we make eukaryotic cells resistant to antibiotics ?



# Reduced drug accumulation in resistant macrophages



## Reduced drug accumulation in resistant macrophages



# Competition for efflux as a mechanism for drug interaction



indomethacin





# Coworking between bacteria and macrophage pumps to reduce ciprofloxacin activity



## **Coworking between bacteria and macrophage pumps** to reduce ciprofloxacin activity



#### **Macrophages**



Cellular concentration (ng/mg prot)								
FQ	W	/Τ	RS					
	Prob. (-)	Prob. (+)	Prob. (-)	Prob. (+)				
CIP	72	263	23	159				
MXF	262	208	241	257				

CIP R; MXF S

# Coworking between bacteria and macrophage pumps to reduce ciprofloxacin activity

				_		
	50	EGD		CLIP		
		Res. (-)	Res. (+)	Res. (-)	Res. (+)	
	CIP	1.2	1.0	5.0	1.0	
Same substrate specificity	MXF	0.6	0.6	0.5	0.25	
of the MFS procaryotic pump and	CIP R; MXF S					
of the ABC eucaryotic pump !	Cellular concentration (ng/mg prot)					
	EO	WT		RS		
		Prob. (-)	Prob. (+)	Prob. (-)	Prob. (+)	
	CIP	72	263	23	159	

262

MXF

CIP R; MXF S

257

241

208

MIC (mg/L)

## Coworking between bacteria and macrophage pumps to reduce ciprofloxacin activity



#### ciprofloxacin

## No effect of bacteria and macrophage pumps on moxifloxacin activity



#### moxifloxacin



## Daptomycin is substrate of P-gp







## **Daptomycin is substrate of P-gp**

### Daptomycin intracellular activity is increased in the presence of P-gp inhibitors



# Putative mechanism of daptomycin transport by P-gp



### anchoring in the membrane towards the hydrophobic chain and extrusion from the membrane

## The past and present efflux team in Brussels

